1. A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial

Link: https://www.nature.com/articles/s41591-025-03995-y Published: Nature Medicine, November 24, 2025

This groundbreaking study tested a new treatment approach for fibrolamellar carcinoma using a vaccine targeting the DNAJ-PKAc fusion protein (the genetic abnormality that causes FLC) combined with two immunotherapy drugs (nivolumab and ipilimumab). The trial enrolled 16 patients, mostly young people and teenagers with advanced disease. The vaccine was designed to teach the immune system to recognize and attack cancer cells containing this specific fusion protein.

The results were promising: 75% of patients who completed the initial treatment phase saw their disease either shrink or stay stable. Three patients had partial responses (their tumors shrank significantly). The treatment was generally safe, with side effects similar to those seen with immunotherapy alone. Importantly, all patients who responded to treatment also showed strong immune responses against the fusion protein. The study demonstrated that this approach could work even in cancers with very few genetic mutations, suggesting a new strategy for targeting “undruggable” cancer-causing proteins through the immune system.

2. Liver Cancer Multi-Omics Reveals Diverse Protein Kinase A Disruptions Convergently Produce Fibrolamellar Hepatocellular Carcinoma

Link: https://www.nature.com/articles/s41467-024-55238-2 Published: Nature Communications, December 30, 2024

This massive study analyzed RNA data from over 1,400 liver tumor samples to better understand FLC at a molecular level. The researchers created a comprehensive “signature” – essentially a fingerprint of gene activity patterns – that can definitively identify FLC tumors. They analyzed 220 FLC samples along with samples from other liver cancers including hepatocellular carcinoma, hepatoblastoma, and cholangiocarcinoma.

The study made several important discoveries: First, all FLC tumors share the same molecular signature regardless of which specific genetic change caused the disease (whether it’s the common DNAJB1-PRKACA fusion or rarer variants). Second, primary tumors and metastases are remarkably similar, with only 0.6% of genes showing differences between them. The researchers also used spatial analysis to show which changes occur in tumor cells versus surrounding tissue. This signature can now be used to diagnose FLC more accurately, validate research models, and potentially identify new treatment targets.

3. Fibrolamellar Hepatocellular Carcinoma: Advances, Challenges and Opportunities in a Rare Malignancy

Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12576631/ Published: World Journal of Gastrointestinal Oncology, 2025

This comprehensive review article summarizes the current state of knowledge about fibrolamellar carcinoma for clinicians. FLC is extremely rare, accounting for less than 5% of primary liver tumors, with an incidence of only 0.2 cases per million people per year. Unlike regular liver cancer, FLC typically affects teenagers and young adults (ages 10-35) who have healthy livers without cirrhosis or hepatitis.

The article emphasizes that surgical removal remains the best treatment when possible, with about 70% of patients having operable disease at diagnosis. However, recurrence rates are high – between 33-100% of patients experience cancer return, typically within 20-48 months after surgery. The review highlights the characteristic DNAJB1-PRKACA gene fusion found in virtually all cases and discusses how this unique genetic signature offers hope for developing targeted therapies. The authors note that despite ongoing research into systemic treatments, there’s still no standard effective drug treatment, making clinical trials crucial.

4. Fibrolamellar Hepatocellular Carcinoma (FL-HCC) Epidemiology, Survival Characteristics, and Outcomes: SEER Database Study

Link: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16213 Published: Journal of Clinical Oncology (ASCO Abstract), 2024

This epidemiology study analyzed data from the SEER national cancer database covering 20 years (2000-2020) to understand who gets FLC and how they fare. The researchers identified 362 confirmed FLC cases with a median age of 27 years at diagnosis. The disease was more common in males (62%) and whites (78%), though notably the incidence appears to be rising – from 1.9% of liver cancers in 2005 to 5.8% in 2020.

About one-quarter of patients presented with stage IV (most advanced) disease at diagnosis. Unlike regular liver cancer, the classic tumor marker AFP (alpha-fetoprotein) was positive in only 16% of FLC patients, making it unreliable for screening. Treatment patterns showed that about half received surgery and half received chemotherapy, with only 11% receiving radiation. The study provides important baseline data showing the rarity of this disease and the challenges in early detection.

5. Clinicopathological Features and Treatment Outcomes of Patients with Fibrolamellar Hepatocellular Carcinoma: A Retrospective Multicenter Study

Link: https://pubmed.ncbi.nlm.nih.gov/40753462/ Published: Annals of Saudi Medicine, July-August 2025

This multicenter retrospective study from Turkey examined 39 patients with histopathologically confirmed fibrolamellar hepatocellular carcinoma. The researchers assessed demographics, prognosis, and treatment outcomes – particularly systemic therapies. The 5-year survival varied dramatically by stage: 80% in stage 1, 57% in stage 2, 53% in stage 3, and 0% in stage 4, highlighting the critical importance of early detection.

The study analyzed treatment responses in metastatic patients and performed progression-free survival (PFS) and overall survival (OS) analyses for first-line treatments. The findings underscore the poor prognosis for advanced-stage disease and the urgent need for effective systemic therapies. The research provides valuable real-world data on treatment patterns and outcomes across multiple medical centers in Turkey.

6. Fibrolamellar Hepatocellular Carcinoma Treated with Chemotherapy and Immunotherapy: A Rare Entity with Unique Characteristics

Link: https://online.reed.es/DOI/PDF/ArticuloDOI_11021.pdf Published: Revista Española de Enfermedades Digestivas, 2025

This case report describes a patient with advanced FLC who was treated with a combination of chemotherapy and immunotherapy. The doctors identified the characteristic DNAJB1-PRKACA fusion in the tumor, which is now considered the defining biomarker for FLC and is present in over 90% of cases. This fusion is crucial for diagnosis because it distinguishes FLC from other liver cancers.

The report emphasizes that most FLC cases are caught late, but up to 70% of patients might still benefit from surgery or liver transplant. Unfortunately, no chemotherapy combination has proven consistently effective in prospective trials, and FLC appears resistant to most standard cancer drugs. The limited data suggests platinum-based chemotherapy may be among the better options. The case highlights the ongoing challenge of finding effective drug treatments for this rare cancer.

7. Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review – Diagnosis, Imaging, and Management

Link: https://journals.lww.com/journalacs/fulltext/2023/02000/fibrolamellar_hepatocellular_carcinoma_.16.aspx Published: Journal of the American College of Surgeons, February 2023

This systematic review examined all published research through July 2022 on how to diagnose, image, and treat FLC. The authors emphasize that FLC is extremely rare and has unique features: it occurs in young people without underlying liver disease, has distinctive microscopic appearance, and carries the DNAJB1-PRKACA fusion in nearly all cases. This fusion creates an abnormal chimeric protein that drives the cancer.

The review confirms that surgery remains the only potentially curative treatment, but highlights a major problem: even after complete tumor removal, high recurrence rates occur. Despite this, many recurrences can be surgically removed again with reasonably good survival outcomes. The role of chemotherapy remains unclear – there’s insufficient evidence to say whether it helps. The authors call for more collaborative research and clinical trials specific to FLC rather than grouping it with regular liver cancer.

8. Treatment and Prognosis of Fibrolamellar Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10073062/ Published: Journal of Gastrointestinal Surgery, April 2023

This meta-analysis pooled data from multiple studies to get a clearer picture of FLC outcomes and treatment effectiveness. The researchers systematically reviewed recent literature on FLC treatment outcomes, focusing on survival rates and prognostic factors. FLC is confirmed as a rare disease affecting less than 1% of liver cancer patients, typically occurring in younger people without the usual risk factors like hepatitis or cirrhosis.

The analysis examined survival at different time points: 1-year, 3-year, and 5-year overall survival rates. The study particularly focused on outcomes in patients who underwent surgical resection versus those who couldn’t have surgery. Key findings included data on recurrence patterns and the importance of achieving complete tumor removal (R0 resection) for better survival. The authors note that while FLC may have a somewhat better prognosis than regular hepatocellular carcinoma, the high recurrence rate remains a major challenge.

9. Fighting Rare Cancers: Lessons from Fibrolamellar Hepatocellular Carcinoma

Link: https://www.nature.com/articles/s41568-023-00554-w Published: Nature Reviews Cancer, April 20, 2023

This perspective article by Dr. Sanford Simon tells the personal story of a decade-long journey researching FLC, a rare cancer affecting about 1 in 5 million people. The article discusses the unique challenges in studying rare cancers: missed or wrong diagnoses, lack of information and diagnostic tools, too few samples, and insufficient funding. Yet paradoxically, many major cancer biology advances have come from studying well-defined rare cancers.

The article reveals how research answered fundamental questions about FLC: whether it was one disease or many with similar appearances (it’s one disease), and whether it was inherited or from a somatic mutation (it’s somatic – the DNAJB1-PRKACA fusion). Simon shares both successes and failures in the research journey, providing a roadmap for others fighting rare cancers. The piece emphasizes that despite the challenges, rare cancer research can yield insights that transform our understanding of cancer biology more broadly.

10. Fibrolamellar Hepatocellular Carcinoma (StatPearls)

Link: https://www.ncbi.nlm.nih.gov/books/NBK553113/ Published: StatPearls Publishing, Updated September 26, 2022 (Continuously updated)

This educational resource provides a comprehensive overview of FLC for healthcare professionals. It emphasizes that FL-HCC accounts for less than 1% of all primary liver malignancies and differs significantly from conventional hepatocellular carcinoma in behavior and clinical presentation. Patients with FL-HCC are typically younger and don’t have underlying liver disease or cirrhosis – less than 10% show any cirrhotic changes.

The article covers epidemiology, etiology, histopathology, evaluation, treatment, differential diagnosis, and prognosis. It notes that prompt diagnosis and appropriate care planning are crucial for outcomes. The resource is regularly updated to reflect current medical knowledge and is freely available as part of the StatPearls medical education library, making it a valuable reference for clinicians who may encounter this rare condition.

June, 2023 Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma

Science Advances

March, 2023 Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data

NPJ Precision Oncology

Plain Language Summary

January, 2023 Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DJAJB1-PRKACA

Plain Language Summary

Clinical Cancer Research

October, 2022 Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Cancer

September, 2022 Targeting BCL-XL in Fibrolamellar Hepatocellular Carcinoma

Journal of Clinical Investigation Insight

August, 2022 β-catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma

Hepatology Communications

May, 2022   Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry-based study

Hepatology Communications 

 October, 2021 Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening

Cancer Discovery

Plain Language Summary

February, 2021 DNAJB1-PRKACA in HEK293T Cells

PLOS

Plain Language Summary